ALX Oncology (NasdaqGS:ALXO) Q4 2025 Earnings call February 27, 2026 08:30 AM ET Company ParticipantsBarbara Klencke - Chief Medical OfficerHarish Shantharam - CFOJason Lettmann - CEORamakanth Swayampakula - Managing DirectorConference Call ParticipantsAllison Bratzel - Senior Research AnalystDaniel Braun - AnalystRoger Song - Senior Equity Research AnalystSam Slutsky - Senior Research AnalystOperatorGreetings, and welcome to the ALX Oncology fourth quarter 2025 financial results call and webcast. At this t ...

ALX Oncology (NasdaqGS:ALXO) Q4 2025 Earnings call February 27, 2026 08:30 AM ET Company ParticipantsBarbara Klencke - Chief Medical OfficerHarish Shantharam - CFOJason Lettmann - CEORamakanth Swayampakula - Managing DirectorConference Call ParticipantsAllison Bratzel - Senior Research AnalystDaniel Braun - AnalystRoger Song - Senior Equity Research AnalystSam Slutsky - Senior Research AnalystOperatorGreetings, and welcome to the ALX Oncology Q4 2025 financial results call and webcast. At this time, all par ...

ALX Oncology (NasdaqGS:ALXO) Q4 2025 Earnings call February 27, 2026 08:30 AM ET Speaker5Greetings, and welcome to the ALX Oncology fourth quarter 2025 financial results call and webcast. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the cal ...

Corporate Overview February 2026 NASDAQ GS ALXO © ALX Oncology Inc. All rights reserved. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall thereby any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. 2 Confidential Forward-looking Statements Certain information set forth i ...

Exhibit 99.1 ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anticipates multiple meaningful data sets and milestones in the coming 12 to 18 months - - Evorpacept biomarker strategy validated by data from both the Phase 2 ASPEN-06 gastric cancer trial and the P ...

- Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anticipates multiple meaningful data sets and milestones in the coming 12 to 18 months - - Evorpacept biomarker strategy validated by data from both the Phase 2 ASPEN-06 gastric cancer trial and the Phase 1b/2 breast cancer trial, independently suggesting CD47 overexpression is predictive of evorpacept activity and ...

Core Insights - ALX Oncology Holdings Inc. is participating in multiple upcoming biotech conferences to showcase its advancements in cancer therapies [1][2]. Group 1: Conference Participation - ALX Oncology will attend the Wells Fargo Executive Biotech Summit on February 24-25, 2026, in Lake Tahoe, CA, featuring one-on-one meetings [2]. - The company will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, at 9:10 AM EST in Boston, MA [2]. - ALX Oncology will also participate in the UBS Biotech Summit on March 10, 2026, in Miami, FL, with one-on-one meetings scheduled [2]. Group 2: Company Overview - ALX Oncology is a clinical-stage biotechnology company focused on developing novel therapies aimed at treating cancer and improving patient survival [3]. - The lead therapeutic candidate, evorpacept, is being evaluated in multiple clinical trials across various cancer indications and is positioned as a potential cornerstone therapy in immuno-oncology [3]. - The second pipeline candidate, ALX2004, is an EGFR-targeted antibody-drug conjugate currently undergoing a Phase 1 dose-escalation trial for patients with EGFR-expressing solid tumors [3].

Core Insights - ALX Oncology Holdings Inc. plans to report its fourth quarter and full year 2025 financial results on February 27, 2026, before market open [1] - The company will host a teleconference to discuss the financial results [1] Financial Results Webcast Information - The webcast is scheduled for February 27, 2026, at 5:30 AM PT / 8:30 AM ET [2] - Access to the conference call can be obtained by dialing 1-877-407-0755 or +1-201-389-0913 [2] Company Overview - ALX Oncology is a clinical-stage biotechnology company focused on developing novel therapies for cancer treatment [4] - The lead candidate, evorpacept, is being evaluated in multiple clinical trials across various cancer indications [4] - The second candidate, ALX2004, is an EGFR-targeted antibody-drug conjugate currently in a Phase 1 trial for EGFR-expressing solid tumors [4]

Company Overview - ALX Oncology Holdings Inc. (ALXO) is part of the Medical sector, which includes 928 individual stocks and holds a Zacks Sector Rank of 10 [2] - ALX Oncology is currently rated with a Zacks Rank of 2 (Buy), indicating a positive earnings outlook [3] Performance Metrics - Over the past three months, the Zacks Consensus Estimate for ALXO's full-year earnings has increased by 16.9%, reflecting improved analyst sentiment [4] - ALXO has returned approximately 81.4% year-to-date, significantly outperforming the average gain of 5.3% for Medical stocks [4] - In the Medical - Biomedical and Genetics industry, which includes 449 companies, ALXO is performing better than the average industry gain of 23.6% this year [6] Comparative Analysis - Another Medical stock, Amneal Pharmaceuticals (AMRX), has returned 15.2% year-to-date and has a Zacks Rank of 2 (Buy) [5] - Amneal Pharmaceuticals belongs to the Medical - Drugs industry, which has a lower year-to-date gain of +2.7% and is ranked 146 [7]

Core Viewpoint - ALX Oncology Holdings Inc. has announced the pricing of an underwritten offering of common stock and pre-funded warrants, aiming to raise approximately $150 million to support its clinical development programs and general corporate purposes [1][3]. Group 1: Offering Details - ALX Oncology is selling 76,979,112 shares of common stock at an offering price of $1.57 per share and pre-funded warrants to purchase 18,574,120 shares at $1.569 each [1]. - The gross proceeds from the offering are expected to be around $150 million before deducting underwriting discounts and commissions [1]. - The offering is expected to close on or about February 2, 2026, subject to customary closing conditions [1]. Group 2: Investors and Participation - The financing is led by new investors RA Capital Management and TCGX, with participation from various other investors including 5AM Ventures, Blackstone Multi-Asset Investing, and others [2]. Group 3: Use of Proceeds - The net proceeds from the offering will be used to fund the continued clinical development of evorpacept and the ALX2004 program, as well as for working capital and other general corporate purposes [3]. Group 4: Company Overview - ALX Oncology is a clinical-stage biotechnology company focused on developing novel therapies for cancer treatment, with its lead candidate evorpacept currently in multiple clinical trials [6]. - The second pipeline candidate, ALX2004, is an EGFR-targeted antibody-drug conjugate undergoing a Phase 1 dose-escalation trial in patients with EGFR-expressing solid tumors [6].